Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment. uri icon

authors

  • Adela Wu
  • Garzon-Muvdi, Tomas
  • Jackson, Christopher M
  • Mathios, Dimitrios
  • Theodros, Debebe
  • Cogswell, John
  • Brem, Henry
  • Pardoll, Drew M
  • Lim, Michael
  • Maxwell, Russell
  • Xia, Yuanxuan
  • Cardarelli, Pina
  • Oyasu, Miho
  • Belcaid, Zineb
  • Kim, Eileen
  • Hung, Alice
  • Luksik, Andrew S

publication date

  • April 25, 2019